Home › Valeant misses expectations as loses $89 million in Q4, $116M for full year
 

Keywords :   


Valeant misses expectations as loses $89 million in Q4, $116M for full year

2013-02-28 23:56:10| Biotech - Topix.net

Valeant Pharmaceuticals International missed expectations as it net loss grew in the fourth-quarter and full-year amid higher operating expenses and items related to restructuring and acquisitions.

Tags: year full million expectations

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11100 SMAX
15.11ANABoeing 747JA809518cm660g
15.1114
15.11
15.11PS3 CECH2500A
15.11
15.11T
15.11adidas
More »